Novel CAR-T therapy shows promising safety and durable responses in hard-to-treat multiple myeloma

A signifier 1 objective proceedings led by investigators astatine Mass General Brigham Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center has recovered that an investigational CAR-T therapy tin pb to heavy and durable responses successful radical with relapsed oregon refractory aggregate myeloma. Results are published successful The New England Journal of Medicine.